RecruitingProstate Cancer
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
Eligible age
18+ yrs
Accepts
Men
Locations
7 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib.
Sponsor: AstraZeneca
Where it's recruiting
California
Duarte · San Francisco
Florida
Tampa
Massachusetts
Boston
Missouri
St Louis
South Carolina
Myrtle Beach
Tennessee
Nashville
Utah
Salt Lake City
Source: ClinicalTrials.gov · NCT07336446 · last updated 2026-08-10